

PB 98 of 2020

National Health (Continued Dispensing) Amendment Determination 2020 (No. 1)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health make the following determination.

Dated 28 September 2020

**THEA CONNOLLY**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1 Name

2 Commencement 1

3 Authority 1

4 Schedule 1

Schedule 1—Amendments 2

National Health (Continued Dispensing) Determination 2012 2

1 Name

1. This instrument is the *National Health (Continued Dispensing) Amendment Determination 2020 (No. 1)*.
2. This instrument may also be cited as PB 98 of 2020.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 October 2020.* |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

**3 Authority**

 This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing) Determination 2012

1. Part 1, Section 1.03, definition for ‘*PSA Guidelines’*

*substitute: PSA Guidelines* means the document titled *Guidelines for the Continued Dispensing of eligible prescribed medicines by pharmacists*, issued by the Pharmaceutical Society of Australia.

1. Schedule 1, Part 1, entry for Levonorgestrel with Ethinyloestradiol

*omit from the column headed “Listed Drug”:* Levonorgestrel with Ethinyloestradiol *substitute:* Levonorgestrel with ethinylestradiol

1. Schedule 1, Part 1, entry for Norethisterone with Ethinyloestradiol
2. *omit from the column headed “Listed Drug”:* Norethisterone with Ethinyloestradiol *substitute:* Norethisterone with ethinylestradiol
3. *omit:*

|  |  |  |
| --- | --- | --- |
|  | Pack containing 12 tablets 500 micrograms‑35 micrograms, 9 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral |

1. Schedule 1, Part 2, entry for Fluvastatin

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Capsule 20 mg (as sodium) | Oral |
|  | Capsule 40 mg (as sodium) | Oral |